p16/p53 gene therapy (HepaVec/Merck & Co)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namep16/p53 gene therapy (HepaVec/Merck & Co)
Drug Alias NameAdenovirus gene therapy (HepaVec/Merck)hepatocellular carcinoma gene therapy (HepaVec/Merck)liver tumor gene therapy (HepaVec/Merck)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHepaVec AG fuer Gentherapie
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHepaVec AG fuer GentherapieMerck & Co Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A